Concord Biotech Limited has informed the Exchange regarding 'Updates'.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech's Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025. Standalone revenue from operations grew ~14% YoY to Rs. 27,813 lakhs in Q3 FY26, but profit after tax fell ~8.5% to Rs. 6,778 lakhs (EPS Rs. 6.48 vs Rs. 7.08 YoY). For the nine-month period, both revenue (Rs. 72,918 lakhs) and profit after tax (Rs. 17,324 lakhs) declined compared to Rs. 77,020 lakhs and Rs. 23,103 lakhs in the prior year. The company also recognised a one-time exceptional charge of Rs. 327.54 lakhs toward employee benefits under India's new Labour Codes. Additionally, Mr. Paritosh Trivedi was appointed as Company Secretary, Compliance Officer and Nodal Officer effective February 11, 2026.
Mixed quarter for shareholders — top-line growth in Q3 was offset by margin compression and a sharp YoY decline in nine-month profits, which may weigh on near-term sentiment despite the stock's stable pharma franchise.